

Background: Previous studies on the prevalence of metabolic syndrome in patients with bipolar disorder have reported higher rates than in their respective general populations.

Objective: This study evaluates the prevalence rate and modal subcomponents of metabolic syndrome in 34 patients treated in University Hospital Centre Zagreb, Croatia.

Method: Naturalistic, cross sectional study. Patients were evaluated for the presence of metabolic syndrome according to NCEP ATP-III criteria.

Results: Mean age was 41.1 (SD 12.9). Overall prevalence rate of MetS was 35.3%. Forty seven percent met the criterion for abdominal obesity, 58.8% for hypertriglyceridemia, 23.5 % for low HDL cholesterol, 50.0% for hypertension, and 23.5 for high fasting glucose. There was no difference in the prevalence rate by gender.

Conclusions: Clinical medical monitoring for these parameters is recommended. Psychotropic drugs use may confer differential risk for developing the metabolic syndrome.

P0160

A double-blind, placebo-controlled study with acute and continuation phase of Quetiapine and Lithium in adults with bipolar depression (Embolden I)

A.H. Young¹, A. Carlsson², B. Olausson², B. Paulsson², M. Brecher³. ¹Department of Psychiatry, Institute of Mental Health, The University of British Columbia, Vancouver, BC, Canada ²AstraZeneca, Sodertalje, Sweden ³AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

Background and Aims: Evaluate the efficacy and tolerability of quetiapine and lithium monotherapy for major depressive episodes in bipolar disorder during an acute 8-week period and up to 52-week continuation phase.

Methods: 802 patients (499 bipolar I, 303 bipolar II) were randomized to quetiapine 300mg/d (n=265), quetiapine 600mg/d (n=268), lithium 600mg/d (n=136), or placebo (n=133) for 8 weeks. Primary endpoint was change from baseline to 8 weeks in MADRS total score. After 8 weeks, patients with MADRS ≤ 12 and YMRS ≤ 12 entered a 26- to 52-week continuation phase of quetiapine (300mg/d or 600mg/d) or placebo. Patients on lithium received 300mg/day of quetiapine (results of continuation phase not included here and to be presented separately).

Results: LSM MADRS score change at 8 weeks was -15.36 (quetiapine 300mg/d), -16.10 (quetiapine 600mg/d), -13.60 (lithium), and -11.81 (placebo); $P < 0.001$ for both quetiapine doses, $P = 0.123$ for lithium, versus placebo; LOCF ANCOVA). Quetiapine (both doses)-treated, but not lithium-treated, patients showed significantly greater improvements ($P \leq 0.05$) in MADRS response and remission rates, HAM-D, CGI-BP-S, CGI-BP-Change, and HAM-A at Week 8 versus placebo; MADRS item 10 (suicidal thoughts) improved with quetiapine 600mg/d versus placebo ($P = 0.013$). Most common adverse events considered drug-related included somnolence, dry mouth, and dizziness with quetiapine (both doses) and nausea with lithium.

Conclusions: Quetiapine (300mg/d or 600mg/d) was more effective than placebo for the treatment of acute depressive episodes in bipolar I and bipolar II disorder. Quetiapine treatment was generally well tolerated.

Supported by funding from AstraZeneca Pharmaceuticals LP.

P0161

A double-blind, placebo-controlled study with acute and continuation phase of Quetiapine and Paroxetine in adults with bipolar depression (Embolden II)

S. McElroy¹, A.H. Young², A. Carlsson³, B. Olausson³, A. Nordenhem³, B. Paulsson³, M. Brecher⁴. ¹University of Cincinnati College of Medicine, Cincinnati, OH, USA ²Department of Psychiatry, Institute of Mental Health, The University of British Columbia, Vancouver, BC, Canada ³AstraZeneca, Sodertalje, Sweden ⁴AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

Background and Aims: Evaluate efficacy and tolerability of quetiapine and paroxetine monotherapy for major depressive episodes in bipolar disorder during an acute 8-week period and up to 52-week continuation phase.

Methods: 740 patients (478 bipolar I, 262 bipolar II) were randomized to quetiapine 300mg/d (n=245), quetiapine 600mg/d (n=247), paroxetine 20mg/d (n=122), or placebo (n=126) for 8 weeks. Primary endpoint was change from baseline to 8 weeks in MADRS total score. After 8 weeks, patients with MADRS ≤ 12 and YMRS ≤ 12 entered a 26- to 52-week continuation phase of quetiapine (300mg/d or 600mg/d) or placebo. Patients on paroxetine received 300mg/d of quetiapine (continuation phase results not included here and to be presented separately).

Results: LSM MADRS score change at 8 weeks was -16.19 (quetiapine 300mg/d), -16.31 (quetiapine 600mg/d), -13.76 (paroxetine), and -12.60 (placebo); $P < 0.001$ for both quetiapine doses, $P = 0.313$ for paroxetine, versus placebo; LOCF ANCOVA). Quetiapine (both doses)-treated patients showed significantly greater improvements ($P \leq 0.05$) in MADRS response rate, HAM-D, CGI-BP-S, CGI-BP-Change, HAM-A, and MADRS item 10 (suicidal thoughts) at Week 8 versus placebo; MADRS remission rates improved with quetiapine 600mg/d versus placebo ($P = 0.012$). Paroxetine improved HAM-A scores versus placebo ($P = 0.033$).

Most common adverse events considered drug-related included dry mouth, somnolence, sedation, and dizziness with quetiapine (both doses); dry mouth, sedation, headache, insomnia, and nausea with paroxetine.

Conclusions: Quetiapine (300mg/d or 600mg/d) was more effective than placebo for the treatment of acute depressive episodes in bipolar I and II disorder. Quetiapine treatment was generally well tolerated.

Supported by funding from AstraZeneca Pharmaceuticals LP.

Poster Session II: Cognitive Enhancing Drugs

P0162

Cognitive effects of acute Modafinil treatment in patients with sleep apnea

S.G. Giakoumaki¹, A. Nikolaou¹, S.E. Schiza², N. Sifakas², P. Bitsios¹. ¹Department of Psychiatry and Behavioural Sciences, University of Crete, Heraklion, Greece ²Sleep Disorders Unit, Department of Thoracic Medicine, University of Crete, Heraklion, Greece